Nintedanib

Cat. No.: 0225LY-1106

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Nintedanib operates as a triple vascular kinase inhibitor that suppresses the VEGFR, FGFR, and PDGFR families (with various IC50s ranging from 10 nM to 108 nM) to exert antitumor effects by blocking angiogenesis.

Synonym: BIBF 1120; Intedanib; 656247-17-5; Vargatef; Intedanib; BIBF-1120; Nintedanib (BIBF 1120); (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; Methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate; 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester; methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate; (Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; (Z)-Methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)-phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1h-indole-6-carboxylate; Methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate; Methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate

CAS No.: 656247-17-5

Compound CID: 135423438

Formula: C₃₁H₃₃N₅O₄

Formula Weight: 539.62

Specification

Targets&IC50: PDGFRα: 59 nM (cell free); FGFR1: 69 nM (cell free); FGFR2: 37 nM (cell free); VEGFR1: 34 nM (cell free); VEGFR3: 13 nM (cell free); VEGFR2: 13 nM (cell free)

Relative Density: 1.284 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Nintedanib can be used in pulmonary and oncology studies to evaluate the triple inhibition of VEGFR, PDGFR, and FGFR signaling pathways.